HomeRELAPSING REMITTING MULTIPLE SCLEROSIS

  • SPMS patients have higher cognitive decline than RRMS patients, study reports

    • April 17, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • NICE denies Ocrelizumab for RRMS in UK

    • April 7, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Roche Acquires regenerative MS therapy program focused on remyelination

    • April 5, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • NATCO launches generic version of Aubagio for MS in INDIA

    • April 5, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • First patient enrolled in Ph 3 Trial of ADS-5102 in MS Patients with Walking Impairment

    • April 5, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Novel PET imaging agent to assess treatments for neurological diseases

    • April 4, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Ocrevus shows higher efficacy than Rebif on NEDA in RRMS patients, a recent analysis shows

    • April 2, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • FLX-787 in Multiple Sclerosis displays positive Phase 2 Topline results

    • March 28, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Successful results for Multiple Sclerosis MAb GNbAC1 announced by GeNeuro and Servier in Phase 2b CHANGE-MS Study

    • March 27, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more